CurrentBlue Cross Blue Shield - Rhode IslandPolicy N/A

Genetic testing for mitochondrial disorders

Defines medical necessity criteria, prior authorization and covered CPT codes for genetic testing to diagnose mitochondrial disorders for Medicare Advantage Plans and Commercial Products (BCBSRI). Specifies tests covered when clinical criteria are met and rules for targeted familial variant testing in at-risk relatives.

Policy Summary

PayerBlue Cross Blue Shield - Rhode Island

PolicyGenetic testing for mitochondrial disorders

Policy CodePolicy N/A

Change TypeNo material changes

Effective Date

Next Review Date

Key ActionObtain prior authorization (required for Medicare Advantage; recommended for Commercial) and ensure clinical documentation of signs/symptoms or family history to support medical necessity; only the ordering physician may participate in authorization/appeal processes.

SourceLink

POLICY UPDATE CHANGES

No material clinical or coverage changes to policy.

4CPT codes listed as covered

>=100Minimum genes required in nuclear gene panel

335Number of nuclear genes in 0417U product

Coverage Summary

Scope: This policy (Blue Cross & Blue Shield of Rhode Island) defines medical necessity criteria, prior authorization requirements, and covered CPT codes for genetic testing to diagnose mitochondrial disorders for Medicare Advantage Plans and Commercial Products. Coverage stance: mixed — certain mitochondrial genetic tests are covered when medical criteria are met, and prior authorization is required for Medicare Advantage Plans and recommended for Commercial Products. Status: CURRENT.

Medical Necessity Criteria

Medically necessary genetic testing to establish diagnosis

Genetic testing to establish a genetic diagnosis of a mitochondrial disorder may be considered medically necessary when ALL of the following are met:

ALL of the following

Signs and symptoms of a mitochondrial disorder are present
Genetic testing may eliminate the need for muscle biopsy

Targeted familial variant testing (preconceptional carrier / at-risk relatives)

Targeted genetic testing for a known familial variant in at-risk relatives may be considered medically necessary when ALL of the following are met:

ALL of the following

A variant that is known to be pathogenic for that mitochondrial disorder has been identified in the index case
There is a defined mitochondrial disorder in the family of sufficient severity to cause impairment of quality of life or functional status

Coding

Covered when medical criteria met (Medicare Advantage & Commercial)CPTCovered

0417U	Genomic Unity Comprehensive Mitochondrial Disorders Analysis (whole mitochondrial genome sequence with heteroplasmy detection and deletion analysis; nuclear-encoded mitochondrial gene analysis of 335 nuclear genes; blood or saliva)
81440	Nuclear encoded mitochondrial genes, genomic sequence panel (must include analysis of at least 100 genes including listed genes such as DGUOK, MPV17, OPA1, PDSS2, POLG, POLG2, RRM2B, SCO1, SCO2, SLC25A4, SUCLA2, SUCLG1, TAZ, TK2, TYMP)
81460	Whole mitochondrial genome, genomic sequence, must include sequence analysis of entire mitochondrial genome with heteroplasmy detection
81465	Whole mitochondrial genome large deletion analysis, including heteroplasmy detection, if performed

Provider Actions

Prior Authorization

Prior authorization requirement

Prior authorization is required for Medicare Advantage Plans and is recommended for Commercial Products. Only the ordering physician may participate in authorization, appeal, or other administrative processes; laboratories may not obtain authorization on behalf of the ordering physician.

Applies to: Medicare Advantage; Recommended: Commercial

Denial Risk

Laboratory authorization prohibition and financial liability

If a laboratory provides a service that has not been authorized or if a laboratory or third party improperly obtains authorization, the service will be denied and the financial liability will be the participating laboratory; such violations may result in termination from the BCBSRI provider network.

Documentation Required

Clinical documentation to support medical necessity

Providers must document signs and symptoms consistent with mitochondrial disease or a relevant family history (including an index-case pathogenic variant) and document severity sufficient to impair quality of life or functional status to support medical necessity for testing and authorization.

Background & Evidence

Mitochondrial DNA (mtDNA) and nuclear DNA (nDNA) both contribute to mitochondrial function: human mtDNA contains 37 genes (13 coding subunits of oxidative phosphorylation and 24 involved in translation/assembly), while over 1000 nuclear genes encode proteins that support mitochondria and are produced in the nucleus then imported into mitochondria.

Inheritance differs from Mendelian patterns: mtDNA is maternally inherited so variants in mtDNA are passed only from the mother. Cells contain many copies of mtDNA (rather than a single copy of nDNA), and variants may be present in some copies but not others — this is heteroplasmy, expressed as a percentage from 0% to 100%; clinical expression typically depends on a threshold effect when the proportion of mutated mtDNA exceeds a critical level.

Primary mitochondrial diseases are multisystem and clinically heterogeneous, preferentially affecting high-energy organs (CNS, heart, skeletal muscle). The minimum prevalence is estimated at about 1 in 5000. Disease severity is variable across patients.

Therapies are largely supportive; there are limited disease-specific treatments, with vitamins/cofactors and exercise used empirically and gene transfer approaches still experimental. Genetic testing can improve diagnostic accuracy, has demonstrated diagnostic yield for NGS panels (~15%–25%), and in symptomatic patients a positive genetic result can avoid muscle biopsy and obviate further invasive testing.

Genetic testing approaches vary by suspected disorder and may include mtDNA sequencing and deletion/duplication analysis, nuclear gene panels, or whole-exome/genome strategies depending on clinical context.

Evidence and related concepts

Diagnostic yield (NGS panels)Approximately 15% to 25% for known pathogenic variants

Clinical validity for targeted familial testingExpected to be high for targeted testing of a known familial variant

Heteroplasmy conceptPresence of a mixture of more than one type of mitochondrial DNA within a cell, expressed as percentage (0% to 100%)

Definitions

HeteroplasmyPresence of a mixture of more than one type of mitochondrial DNA within a cell, expressed as percentage of genes that have the variant (0% to 100%).